Clinical Trial Update: ITIL-306 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of ITIL-306 in advanced solid tumors sponsored by Instil Bio has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ITIL-306

Snippet

Sponsor: Instil Bio | Conditions: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED